Needham & Company LLC Reaffirms “Hold” Rating for TransMedics Group (NASDAQ:TMDX)

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

TMDX has been the subject of a number of other research reports. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler lowered their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Robert W. Baird cut their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

NASDAQ TMDX opened at $70.44 on Wednesday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 74.94 and a beta of 2.12. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The company’s 50 day moving average is $68.88 and its two-hundred day moving average is $88.90. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Institutional Trading of TransMedics Group

Hedge funds have recently made changes to their positions in the business. Atlas Capital Advisors Inc. purchased a new position in TransMedics Group in the fourth quarter worth about $31,000. Hager Investment Management Services LLC purchased a new position in shares of TransMedics Group in the 4th quarter worth approximately $33,000. Sachetta LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $40,000. AlphaQuest LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $52,000. Finally, Quarry LP raised its holdings in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.